← Browse by Condition

Medical Condition

diffuse large b cell lymphoma

Total Trials

23

Recruiting Now

23

Trial Phases

Phase 2, Phase 1, EARLY_Phase 1

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — diffuse large b cell lymphoma Clinical Trials

How many clinical trials are currently recruiting for diffuse large b cell lymphoma?

ClinicalMetric currently tracks 23 actively recruiting clinical trials for diffuse large b cell lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 23. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for diffuse large b cell lymphoma?

diffuse large b cell lymphoma research spans Phase 1 (7 trials), Phase 2 (11 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a diffuse large b cell lymphoma clinical trial?

Eligibility criteria for diffuse large b cell lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

7

Phase 2

11

Phase 3

1

Top Sponsors

Peking Union Medical College Hospital 1 trial

Sun Yat-sen University 1 trial

Ruijin Hospital 1 trial

Paolo Caimi, MD 1 trial

University Hospital, Montpellier 1 trial

Recruiting Clinical Trials

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

Peking Union Medical College H...

NCT06517511 Phase 2

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

Sun Yat-sen University

PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma

Ruijin Hospital

NCT07225439 Phase 1

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Paolo Caimi, MD

Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?

University Hospital, Montpelli...

NCT06120166 EARLY_Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

NCT06022029 Phase 1

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

United States, Austr...

OncoNano Medicine, Inc.

NCT02393157 Phase 2

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

New York Medical College

NCT05757219 Phase 2

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

H. Lee Moffitt Cancer Center a...

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

OHSU Knight Cancer Institute

NCT05139017 Phase 2, Phase 3

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

United States, Argen...

Merck Sharp & Dohme LLC

NCT03676504 Phase 1, Phase 2

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

University Hospital Heidelberg

NCT06208735 Phase 1

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

British Columbia Cancer Agency

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

United States, Spain

Leuko Labs, Inc.

NCT07001540 Phase 2

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Fudan University

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

Novartis Pharmaceuticals

NCT04186520 Phase 1, Phase 2

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Medical College of Wisconsin

Frontline of ASCT in High-risk DLBCL

Peking University People's Hos...

NCT03223610 Phase 1, Phase 2

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Cancer Institute (NCI...

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

Argentina, Australia...

NCT06651853 Phase 2

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

The First Affiliated Hospital ...

NCT06005870 Phase 2

Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

Huazhong University of Science...

NCT04844866 Phase 2

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Austria, Belgium, Cr...

Miltenyi Biomedicine GmbH

Related Conditions

follicular lymphoma (7) mantle cell lymphoma (5) non hodgkin lymphoma (3) chronic lymphocytic leukemia (3) high grade b cell lymphoma (2) primary mediastinal large b cell lymphoma (2) small lymphocytic lymphoma (2) marginal zone lymphoma (2) burkitt lymphoma (2) multiple myeloma (2) primary mediastinal large b cell lymphoma pmbcl (2) car t (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology